CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 326 enrolled
Drug / intervention
SER120 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00937378
NCT00937378Phase 3Completed
CompareCT.gov

A Phase III Randomized, Double Blind, Placebo Control, Multicenter Study to Investigate the Efficacy the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia (Non PK Study)

Serenity Pharmaceuticals, Inc.·interventional·Posted Jul 13, 2009·Updated Oct 22, 2020

In Brief

A Phase 3 clinical trial evaluating SER120 and Placebo for Nocturia. Completed, enrolled 326 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNocturia
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 13, 2009
Enrollment StartJun 1, 2009
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.0 years ago

Interventions

SER120drug

Nasal Spray, once a day

Placebodrug

Nasal Spray